 
 
 
SIXTIETH WORLD HEALTH ASSEMBLY WHA60.20 Agenda item 12.18 23 May 2007 
Better medicines for children 
 
The Sixtieth World Health Assembly, 
Having considered the report on better medicines for children; 
Recalling resolutions WHA39.27, WHA41.16 an d WHA47.13 on the rational use of drugs, 
WHA41.17 on ethical criteria for medicinal drug promotion, WHA43.20 and WHA45.27 on the 
WHO Action Programme on Essential Drugs, WHA47.12 on the role of the pharmacist in support of 
the WHO revised drug strategy, WHA49.14 and WHA 52.19 on the revised drug strategy, WHA54.11 
on the WHO medicines strategy, and WHA58.27 on improving the containment of antimicrobial 
resistance; 
Recognizing the efforts of WHO in collaboration with governments, other organizations in the 
United Nations system, universities, the private sector, nongovernmental organizations and funding 
agencies in areas related to improving access to better medicines for children; 
Aware of the core components of WHO’s glob al framework for expanding access to essential 
medicines; 
Wishing to promote evidence-based selection and use of medicines for children by health 
providers and carers;  
Aware that there are regional initiatives to a ddress inadequate access to essential medicines for 
children; 
Wishing to ensure better access to essential me dicines for children as a prerequisite for 
achieving health outcomes as set out in the interna tionally agreed health-re lated devel opment goals, 
including those contained in the Millennium Declaration; 
Aware that the lack of access to essential me dicines of assured quality continues to pose 
significant risks of high morbidity and mortality in children, especially those u nder five years of age; 
Recognizing the ongoing work of the Inter governmental Working Group on Public Health, 
Innovation and Intellectual Property and the need to  ensure harmonization of WHO’s work on access 
to essential medicines; 
Concerned that children can be further disadvant aged by lack of physical and economic access 
to essential medicines, especially  in vulnerable communities; WHA60.20 
 
 
  
 
 
2 Recognizing that many countries do not have the requisite capacity to regulate and control 
medicines for children; 
Aware that many manufacturers of essential medi cines have neither developed nor produced 
appropriate dosage forms and strengths of medicines for children; 
Concerned that there is insufficient investme nt in the clinical trials, development and 
manufacture of medicines for children; 
1. URGES Member States: 
(1) to take steps to identify appropriate dosage forms and strengths of medicines for children, 
and to encourage their manufacture and licensing; 
(2) to investigate whether currently available medicines could be formulated to make them 
suitable for use in children; 
(3) to conduct surveillance of antimicrobial resistance of locally available and commonly 
prescribed medicines for children; 
(4) to encourage research and development of appropriate medicines for diseases that affect 
children, and to ensure that high-quality clini cal trials for these medicines are conducted in an 
ethical manner; 
(5) to facilitate timely licensing of appropria te, high-quality and affordable medicines for 
children and innovative methods for monitoring the safety of such medicines, and to encourage the marketing of adequate paediatric formulati ons together with newly developed medicines;  
(6) to promote access to essential medicines for children through inclusion, as appropriate, of 
those medicines in national medicine lists, a nd procurement and reimbur sement schemes, and to 
devise measures to monitor prices;  
(7) to collaborate in order to facilitate innova tive research and development on, formulation 
of, regulatory approval of, provision of adequate  prompt information on, and rational use of, 
paediatric medicines and medicines authorized fo r adults but not approved for use in children;  
(8) to use all necessary administrative and legi slative means including, where appropriate, the 
provisions contained in international agreemen ts, including the agreement on Trade-Related 
Aspects of Intellectual Property Rights, in order to promote access to essential medicines for children; 
2. REQUESTS the Director-General: 
(1) to promote the development, harmonization a nd use of standards for clinical trials of 
medicines for children; to revise and regularly u pdate the Model List of Essential Medicines in 
order to include missing essential medicines fo r children, using evidence-based clinical 
guidelines; and to promote application of such guidelines by Member States and international 
financing bodies, with initial focus on treatme nts for HIV/AIDS, tuberculosis, malaria and 
chronic diseases;   WHA60.20 
 
 
  
 
 
  3  (2) to ensure that all relevant WHO programmes, including but not limited to that on 
essential medicines, contribute to making safe and effective medicines as widely available for 
children as for adults; 
(3) to promote the development of internationa l norms and standards for quality and safety of 
formulations for children, and of the regulatory capacity to apply them;  
(4) to make available eviden ce-based treatment guidelines and independent information on 
dosage and safety aspects of essential medicines for children, progressively to cover all 
medicines for children, and to work with Member  States in order to implement such guidelines;  
(5) to collaborate with governments, other or ganizations of the United Nations system, 
including WTO and WIPO, donor agencies, nongovernmental organizations and the 
pharmaceutical industry in order to encourage fa ir trade in safe and ef fective medicines for 
children and adequate financing for securi ng better access to medicines for children; 
(6) to report to the Sixty-second World Health  Assembly, and subsequently as appropriate, 
through the Executive Board, on progress achieved, problems encountered and specific actions 
needed to further promote better access to medicines for children. 
Eleventh plenary meeting, 23 May 2007 
A60/VR/11 
 
=     =     = 